Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs - Wikidata - awgldk - TriplyDB

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

http://www.wikidata.org/entity/Q28396888

about

Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling Activities of N,N'-Diarylurea MMV665852 analogs against Schistosoma mansoni Bioactive lipid profiling reveals drug target engagement of a soluble epoxide hydrolase inhibitor in a murine model of tobacco smoke exposure The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain An immunoassay to evaluate human/environmental exposure to the antimicrobial triclocarban Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.Epoxyeicosatrienoic acid-dependent cerebral vasodilation evoked by metabotropic glutamate receptor activation in vivo.Post-exposure administration of diazepam combined with soluble epoxide hydrolase inhibition stops seizures and modulates neuroinflammation in a murine model of acute TETS intoxication Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.Development of an online SPE-LC-MS-based assay using endogenous substrate for investigation of soluble epoxide hydrolase (sEH) inhibitors.Epoxyeicosatrienoic acids enhance axonal growth in primary sensory and cortical neuronal cell cultures.Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies.Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures.Soluble Epoxide Hydrolase Pharmacological Inhibition Ameliorates Experimental Acute Pancreatitis in Mice.Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats.Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo.Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models.Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.Förster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase.Epoxyeicosanoids promote organ and tissue regeneration.11,12-Epoxyecosatrienoic acids mitigate endothelial dysfunction associated with estrogen loss and aging: Role of membrane depolarization.Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis.Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis.Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t-TUCB in horses with experimentally induced radiocarpal synovitis.Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage.

P2860

Q24616753-A182EB19-DC9E-451C-BB05-F568BA8E52E6 Q24618018-02C2C336-4040-4C52-96FF-2C2A6DD4BC46 Q27684895-2D41A1EC-8323-4868-8F04-4FC5CC4BBDB8 Q28248377-296108E1-5FA9-4E0D-89F6-94D67FF89504 Q28389729-9048B471-48CD-4404-A100-4B5325B06FED Q28391885-DED955DF-B8B6-436E-B0BA-E1A4DFC52777 Q28392416-8EF23735-FC2B-4090-8A8A-1AFF86292EB4 Q28395553-DD41B1BE-C829-4F23-AB1A-15D50A398A23 Q33744236-F1FFAB38-7FD1-4B53-AF6D-B83E5B548346 Q33908066-9FF3459D-82C2-4F24-AC6D-7CCFA595D3A9 Q34644088-EC107168-621E-48A9-A3D8-2C41F6FC6F35 Q34783515-6307771B-6607-4F4D-B4AE-F9C6B9FF436F Q34836888-FEB2918D-B9F8-4EAB-9858-A32098A0B561 Q34842312-DAA95DEE-BA58-4E59-AB98-E592EB92017B Q35030893-28C4BCDC-3580-4FB6-9E62-A5F13AD26C45 Q35069446-7FAEE986-1650-4564-9832-E8D80C0535AD Q35897881-159C7205-BBAD-4E89-94B9-D2ADDE39AA57 Q36024898-CB0C199F-5538-4822-B84F-0782AF19D9B0 Q36312752-4B4D08A3-379D-48FE-AF63-CF67E1F5BE37 Q36527885-3797CB36-5DA8-46BB-B239-0DDE9C92E30B Q36625617-00A068C6-29DA-4820-8FE9-2CB2C1C9FC86 Q36658386-E3C54AC5-B259-4ABB-A5D6-1FE157A2C88B Q36681141-D9FA312E-49B2-4475-88DD-BCCF1EFD0744 Q36756985-D6F32F1F-434E-478F-801A-F8167F552F5B Q36784547-C598AA75-99BE-4086-B319-4352E297C398 Q37104034-0CCA519C-8DD9-4351-B218-891CBC5D58B2 Q37150118-4A8FB2F9-7106-4E0A-A81D-1AFF573C8159 Q37250368-04612229-FCEB-4F9B-B942-7F511B2E7A41 Q37440238-FF18CE41-2310-47F1-80D2-FC9A06F529C9 Q37641590-D6C53D2C-9297-43C9-B130-2D74DDE3043F Q39659143-419AFBF4-A7E6-46BF-86FE-702D755B18E6 Q40919250-EEB25A92-8DC4-480E-835D-AE2EBB34017A Q41486228-DE256089-8E61-4BA0-A2CA-6211ED659250 Q41642115-8EABAB8A-6FF6-453C-9A2C-B102C9C429C9 Q43160120-E1FF9D4A-26F8-4B38-B82A-F478C6549A05 Q46415634-318BD587-3498-4B71-BD8E-6477F1A33890 Q46442002-74AEA60D-6E62-47D2-A91A-B101A43A9FDC

P2860

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

http://www.wikidata.org/entity/Q28396888

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@ast

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@en

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@nl

type

label

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@ast

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@en

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@nl

prefLabel

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@ast

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@en

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@nl

P1433

Q28396888-CE777E6B-54F5-4F55-B23D-01D6633EF24C

P1476

Q28396888-4EB378F8-B6E3-4BA3-85D7-9EE1E84F6BE8

P2093

Q28396888-451BED5D-1447-428E-9A40-887FA55274B8

Q28396888-65325D30-BA9C-488E-A356-A0E4A5E31196

Q28396888-AB2572F0-E503-46F9-B300-453054108093

Q28396888-AB7F41E6-FE1A-4BB9-9585-7A59000FBB6A

Q28396888-B11E29F0-04D3-48F5-864F-E8FD9A40B9BA

Q28396888-EBF7BA26-49BC-4E4A-B6C7-B89AF9CB4402

P2860

Q28396888-05170F16-CC52-4790-B5B4-01BA62091B8C

Q28396888-0D2EF2CF-4E56-4A79-9E12-6D52995E9178

Q28396888-10943DA8-EE8D-424C-8CF9-908F6D32195C

Q28396888-22EFE262-E1E5-4FDB-8F20-D43EDFC3ABCE

Q28396888-2D402502-ED51-47D1-BEF0-37F7130983C4

Q28396888-32C21434-A25E-4DB2-9804-7864F2B90FF6

Q28396888-3747FF2D-B666-45A9-A57B-C0B3742B5921

Q28396888-3885AE42-5E40-4D41-871B-6FEDE5490AB3

Q28396888-3C097C1D-E76F-4158-862C-BBDA17AAF50A

Q28396888-43AB77E2-EFF1-4E79-B9F0-C9AECC19C3A7

P304

Q28396888-F6A0DCF9-9585-4989-A2AA-14F780F0A7FE

P31

Q28396888-7F58EF59-3203-4932-9911-1472C080E37A

P356

Q28396888-2DFDF35B-0404-4280-8434-1249F4BA1DF7

P407

Q28396888-D094AC70-2F4B-48C8-89AC-884157F5EE89

P433

Q28396888-8D40378E-2E29-4A6A-BEC6-796784157A40

P478

Q28396888-A7191EA9-2C86-437F-A031-E116F20C8781

P50

Q28396888-A0B5F37B-5C07-4A3E-AE1C-15C0A9AC4C9E

Q28396888-EC557B90-3F9A-41F2-948B-FB863C1540EC

P577

Q28396888-4B5D95E2-0764-44B7-8E4E-1F2B58B96AD7

P5875

Q28396888-D3CB985D-4E0B-470E-B82F-634AA0AD3B3B

P698

Q28396888-EB607CB6-F979-45DE-8B75-EA827D23EAC5

P921

Q28396888-EFF84B51-7D85-4EDD-A1FF-52E91D980F3F

P932

Q28396888-C5C9DDEC-7C2E-4CF8-8B9D-191F26574DCB

P356

J.EJPS.2010.03.018

P1433

European Journal of Pharmaceutical Sciences

P1476

Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs

@en

P2093

Hsing-Ju Tsai

http://www.w3.org/2001/XMLSchema#string

In-Hae Kim

http://www.w3.org/2001/XMLSchema#string

Jun Yang

http://www.w3.org/2001/XMLSchema#string

Paul D Jones

http://www.w3.org/2001/XMLSchema#string

Sung Hee Hwang

http://www.w3.org/2001/XMLSchema#string

Takeo Kasagami

http://www.w3.org/2001/XMLSchema#string

P2860

Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice

Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats

Arachidonic acid cytochrome P450 epoxygenase pathway

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Epoxide hydrolases: their roles and interactions with lipid metabolism

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

Differential induction of hepatic drug-metabolizing enzymes by fenvaleric acid in male rats

Soluble epoxide hydrolase: a novel therapeutic target in stroke

Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation

Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain

P304

222-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPS.2010.03.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Christophe Morisseau

Bruce D. Hammock

P577

2010-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42832761

http://www.w3.org/2001/XMLSchema#string

P698

20359531

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

3285443

http://www.w3.org/2001/XMLSchema#string